SS-31 and MOTS-c are the two compounds most often filed under the label mitochondrial peptides, and the label hides how little they have in common. One is a small synthetic molecule engineered to lodge in the mitochondrial inner membrane. The other is a natural peptide that mitochondria themselves encode. They intersect at the organelle and almost nowhere else, which makes the comparison genuinely useful for deciding which literature applies to which research question.
SS-31: a synthetic peptide aimed at a lipid
SS-31, also known as elamipretide and originally one of the Szeto-Schiller peptides, is a designed tetrapeptide, four residues with alternating aromatic and basic side chains (D-Arg, dimethyl-Tyr, Lys, Phe). That alternating motif is the engineering: it lets the peptide concentrate more than a thousandfold in the mitochondrial inner membrane regardless of membrane potential.
Its target is not a protein receptor at all. SS-31 binds cardiolipin, the distinctive double-phospholipid found almost exclusively in the inner mitochondrial membrane, where it scaffolds the respiratory chain complexes. Birk and colleagues showed in 2013 that SS-31's interaction with cardiolipin protects the electron carrier cytochrome c in its productive role and re-energises ischaemic mitochondria. Szeto's 2014 pharmacology review lays out the broader case: where cardiolipin is damaged or remodelled, respiratory efficiency drops and electron leak rises, and a cardiolipin-binding agent is a way at that lesion.
Because it was developed as a drug, elamipretide has what few research peptides have: a real clinical trial programme, spanning heart failure, mitochondrial myopathy and Barth syndrome, the rare disease in which a genetic defect of cardiolipin remodelling is the underlying lesion and where the compound's development ultimately concentrated. We cover that regulatory story separately in SS-31, elamipretide and FDA approval; the short version is that the pharmaceutical product and research-grade SS-31 are not the same article, whatever the shared sequence.
MOTS-c: a peptide the mitochondrion encodes
MOTS-c comes from the opposite direction. It is a 16-amino-acid peptide encoded within the mitochondrial genome itself, inside the 12S ribosomal RNA gene, one of the family of mitochondrial-derived peptides that also includes humanin. Lee and colleagues described it in 2015 and reported that it acts on cellular metabolism, principally through the AMPK pathway, promoting insulin sensitivity and resisting diet-induced obesity in mice.
Where SS-31 stays in the membrane, MOTS-c behaves like a signalling hormone. It circulates, its levels respond to exercise, and under metabolic stress it can move into the cell nucleus and influence gene expression, an unusual arrangement in which the mitochondrial genome talks back to the nuclear one. Reynolds and colleagues showed in 2021 that exercise induces MOTS-c in humans and that treated aged mice improved physical performance, which planted the compound firmly in exercise-mimetic and metabolic-ageing research.
Its human interventional record is early: a small amount of clinical work exists, and nothing approaching elamipretide's programme. Most MOTS-c findings are cell and animal biology.
The comparison in one frame
Mechanistically the two answer different questions. SS-31 is about the hardware: membrane integrity, respiratory chain efficiency, protection under ischaemic or genetic cardiolipin stress. MOTS-c is about the signalling: metabolic regulation, AMPK, exercise physiology. A protocol interested in mitochondrial bioenergetics as such is reading the SS-31 literature; one interested in metabolic adaptation is reading the MOTS-c literature. Citing one body of work in support of the other is the error to avoid, and it is common in secondary write-ups precisely because both compounds carry the mitochondrial label.
Structurally, one is a four-residue synthetic with unnatural amino acids, the other a 16-residue natural sequence. They share no chemistry, no receptor and no pathway upstream of the organelle itself.
Formats in research
Both compounds are supplied for research in multiple formats: SS-31 as a nasal spray, and MOTS-c as a vial or nasal spray. As with every comparison in this series, published findings attach to the molecule and route the study used, and a certificate of analysis is the link between a vial and the literature written about its contents.
The takeaway
SS-31 and MOTS-c share a filing category and nothing else. SS-31 is an engineered cardiolipin-binding tetrapeptide with a genuine clinical development history centred on diseases of mitochondrial membrane biology. MOTS-c is a mitochondrially encoded signalling peptide whose research story is metabolic and still mostly preclinical. Calling them both mitochondrial peptides is true and almost entirely unhelpful; the organelle is where their similarity ends.
All products are intended for research use only. Not for human consumption. Must be 21 years of age or older to purchase.
References
1. Birk, A. V., Liu, S., Soong, Y., et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology, 24(8), 1250-1261.
2. Szeto, H. H. (2014). First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. British Journal of Pharmacology, 171(8), 2029-2050.
3. Lee, C., Zeng, J., Drew, B. G., et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism, 21(3), 443-454.
4. Reynolds, J. C., Lai, R. W., Woodhead, J. S. T., et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications, 12(1), 470.
